Skip to main content
Clinical Trials/IRCT20220305054196N4
IRCT20220305054196N4
Recruiting
Phase 3

Investigating the effect of methylphenidate on the level of consciousness in loss of consciousness patients due to poisoning in Loghman Hakim Hospital in Tehran in 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
64
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age 18 years and above
  • Informed consent of the legal guardian of the patient to participate in the study
  • Having decreased consciousness due to poisoning (GCS 13 and below)
  • Having the ability to move to measure the movement

Exclusion Criteria

  • History of allergy to methylphenidate
  • Po intolerance
  • Unstable vital signs
  • Pregnancy and lactation in female patients
  • Receiving a specific antidote (example: Flumazenin, Naloxone, etc.)
  • Having mental retardation, blindness, deafness
  • Having a history of brain damage, high blood pressure, ischemic heart disease
  • Having epilepsy

Outcomes

Primary Outcomes

Not specified

Similar Trials